iifl-logo

Healthcare Sector

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Download App
image

Indranil Sen has resigned to seek possibilities outside of the organisation.

image

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

image

Against its annual contracted value of USD50m supplies for Librela, Syngene has supplied USD94m worth of Librela to Zoetis over the past 13 months, which likely implies that Librela supplies to Zoetis will continue to taper off in CY24 and will present a tough base for Syngene going ahead. Syngene shipped just USD2m worth of Librela in Feb’24 vs USD21/13m in Dec’23/Jan’24 respectively.

image

The settlement agreement opens the door for Yesafili, a planned biosimilar of Eeylea (aflibercept) injection, to be sold in Canada.

image

Apollo Hospitals, KIMS, and Fortis Healthcare all declined about 2%.

image

This approval adds to Strides' list of products in the HIV treatment category through the PEPFAR pathway, totaling 15 products

image

The product is bioequivalent and therapeutically equivalent to Vascepa (Reference Listed Drug) and will be produced in Bengaluru.

image

SEBI mandates that promoters cannot hold more than 75% of a company's stake, and Glenmark has until August 2024 to meet this requirement

image

It was mentioned that at the end of the inspection, a Form 483 was given with one procedural observation.

image

Tyvalzi™ is designed to treat cerebral ischemic stroke and is a first-in-class drug developed by Pharmazz for potential global use

Download App
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.